Metrovacesa (BME:MVC) Stock Faces 257.9% Earnings Surge Questioning Bearish Narratives

Metrovacesa (BME:MVC) has put fresh numbers on the table for H1 2026, with trailing twelve month revenue of €891.3 million and Basic EPS of €0.59, alongside year-on-year earnings growth of 257.9%. Over recent periods, revenue has moved from €422.7 million in H2 2024 to €575.8 million in H2 2025, while EPS shifted from €0.08 to €0.48 over the same halves. This sets up a very different earnings profile to just a year ago. With the net margin for the trailing period at 8% versus 2.4% in the prior year and a €36.9 million one off loss still in the numbers, investors are likely to read this set of results primarily through a margins and quality-of-earnings lens.

See our full analysis for Metrovacesa.

With the headline figures in place, the next step is to see how these margins and growth trends compare with the most widely held narratives around Metrovacesa and whether the latest report backs them up or starts to pull the story in a different direction.

See what the community is saying about Metrovacesa

257.9% earnings swing meets a €36.9m one off hit

• Over the last 12 months, Metrovacesa reported earnings growth of 257.9% alongside a €36.9 million one off loss, with the trailing net margin at 8% versus 2.4% a year earlier.
• Bulls argue that margin-focused project selection and high presale coverage can support profit durability, yet the presence of a large one off loss and a trailing P/E of 30.5x compared with 11.7x for the European real estate industry raises questions about how much of the recent profit strength is repeatable.
  • The bullish view highlights high visibility from a sales backlog and a focus on higher margin, energy efficient projects. At the same time, the data shows the latest 12 month margin uplift sits alongside that €36.9 million non recurring loss.
  • Supporters also point to prior years of strong earnings growth. However, the recent move from a trailing 2.4% margin to 8% leaves open how earnings would look without that one off distortion.

Supporters who think margins can keep holding up or improve from here may want to see how that case is built out beyond the headline growth and one off items in the full bullish narrative for Metrovacesa 🐂 Metrovacesa Bull Case.

Revenue jumps from €422.7m to €575.8m test bearish demand concerns

• Half yearly data shows revenue at €422.7 million in H2 2024 rising to €575.8 million in H2 2025, while H1 2025 revenue was €132.5 million with a net loss of €15.5 million, highlighting how dependent recent profitability has been on a strong second half.
• Bears warn that stretched housing affordability and limited geographic reach could slow future sales, yet the recent pattern of higher H2 revenue and a move from a €15.5 million loss in H1 2025 to €72.4 million net income in H2 2025 indicates buyers were still absorbing projects at higher volumes across that period.
  • Critics focus on the risk that record house prices and a concentrated Spanish footprint could weaken demand, but the reported H2 revenue step from €422.7 million to €575.8 million does not yet show that effect in the historical data provided.
  • The bearish narrative also flags low margin land disposals, and while those may affect future profitability, the current figures show that core activity in the latest H2 period supported a much stronger profit outcome than the loss reported in H1 2025.

Readers weighing whether these reported revenue trends really challenge the cautious view on demand can walk through the full reasoning in the bearish narrative for Metrovacesa 🐻 Metrovacesa Bear Case.

High 30.5x P/E versus peers and DCF fair value of €12.97

• Metrovacesa trades on a trailing P/E of 30.5x compared with 11.7x for the wider European real estate industry and 11.2x for peers, while a DCF fair value of €12.97 sits above the current share price of €11.46.
• Consensus narrative suggests modest forecast earnings growth of about 4.9% per year and revenue growth of about 2.5% per year, so investors are weighing a relatively high P/E and slower projected growth rates against a DCF fair value that is higher than the current market price.
  • What stands out is that the trailing 8% net margin and very strong 12 month earnings growth are already reflected in a P/E multiple well above sector averages, even though the growth forecasts are below the wider Spanish market expectations.
  • Supporters of the consensus view may see the gap between the €11.46 share price and the €12.97 DCF fair value as room for upside, while others may focus more on the premium P/E and moderate growth forecasts when thinking about how much they are paying for those earnings.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Metrovacesa on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With Metrovacesa, the debate between upside potential and real risks is clearly alive, so it makes sense to look through the data yourself and move quickly to shape your own view using the 3 key rewards and 1 important warning sign.

See What Else Is Out There Beyond Metrovacesa

Metrovacesa combines a high 30.5x P/E, moderate consensus growth forecasts and dependence on strong second half results, which may limit comfort around repeatability.

If you are questioning that premium P/E and want ideas where pricing looks tighter against fundamentals, check out the 237 high quality undervalued stocks while this earnings season is still fresh in mind.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com